BACKGROUND: Treatment of rare severe side effects of vaccinia virus (VACV) immunization in humans is currently very challenging. VACV possesses two immunologically distinct virion forms in vivo - intracellular mature virion (MV, IMV) and extracellular virion (EV, EEV). METHODS: Antibody-mediated therapeutic efficacy was determined against VACV infection in a small animal model of progressive vaccinia. The model consisted of severe combined immunodeficiency mice infected with VACV New York City Board of Health vaccine strain and treated with monoclonal antibodies (mAbs). RESULTS: Here, we show that combination therapy with two fully human mAbs against an immunodominant MV antigen, H3 (H3L), and an EV antigen, B5 (B5R), provides significantly better protection against disease and death than either single human monoclonal or human vaccinia immune globulin, the currently licensed therapeutic for side effects of smallpox vaccination. CONCLUSIONS: The preclinical studies validate that this combination of mAbs against H3 and B5 is a promising approach as a poxvirus infection treatment for use in humans.
BACKGROUND: Treatment of rare severe side effects of vaccinia virus (VACV) immunization in humans is currently very challenging. VACV possesses two immunologically distinct virion forms in vivo - intracellular mature virion (MV, IMV) and extracellular virion (EV, EEV). METHODS: Antibody-mediated therapeutic efficacy was determined against VACVinfection in a small animal model of progressive vaccinia. The model consisted of severe combined immunodeficiencymice infected with VACV New York City Board of Health vaccine strain and treated with monoclonal antibodies (mAbs). RESULTS: Here, we show that combination therapy with two fully human mAbs against an immunodominant MV antigen, H3 (H3L), and an EV antigen, B5 (B5R), provides significantly better protection against disease and death than either single human monoclonal or humanvaccinia immune globulin, the currently licensed therapeutic for side effects of smallpox vaccination. CONCLUSIONS: The preclinical studies validate that this combination of mAbs against H3 and B5 is a promising approach as a poxvirus infection treatment for use in humans.
Authors: K Tomizuka; T Shinohara; H Yoshida; H Uejima; A Ohguma; S Tanaka; K Sato; M Oshimura; I Ishida Journal: Proc Natl Acad Sci U S A Date: 2000-01-18 Impact factor: 11.205
Authors: Juan E Moyron-Quiroz; Megan M McCausland; Robin Kageyama; Alessandro Sette; Shane Crotty Journal: Vaccine Date: 2009-10-12 Impact factor: 3.641
Authors: Mohammed Rafii-El-Idrissi Benhnia; Megan M McCausland; John Laudenslager; Steven W Granger; Sandra Rickert; Lilia Koriazova; Tomoyuki Tahara; Ralph T Kubo; Shinichiro Kato; Shane Crotty Journal: J Virol Date: 2009-09-30 Impact factor: 5.103
Authors: Michael H Matho; Matt Maybeno; Mohammed Rafii-El-Idrissi Benhnia; Danielle Becker; Xiangzhi Meng; Yan Xiang; Shane Crotty; Bjoern Peters; Dirk M Zajonc Journal: J Virol Date: 2012-05-23 Impact factor: 5.103
Authors: D Huw Davies; Sookhee Chun; Gary Hermanson; Jo Anne Tucker; Aarti Jain; Rie Nakajima; Jozelyn Pablo; Philip L Felgner; Xiaowu Liang Journal: J Immunol Date: 2014-07-14 Impact factor: 5.422
Authors: Xiangzhi Meng; Thomas Kaever; Bo Yan; Paula Traktman; Dirk M Zajonc; Bjoern Peters; Shane Crotty; Yan Xiang Journal: Virology Date: 2018-03-17 Impact factor: 3.616
Authors: Thomas Kaever; Xiangzhi Meng; Michael H Matho; Andrew Schlossman; Sheng Li; Inbal Sela-Culang; Yanay Ofran; Mark Buller; Ryan W Crump; Scott Parker; April Frazier; Shane Crotty; Dirk M Zajonc; Bjoern Peters; Yan Xiang Journal: J Virol Date: 2014-07-16 Impact factor: 5.103
Authors: Kavita Singh; Apostolos G Gittis; Rossitza K Gitti; Stanley A Ostazeski; Hua-Poo Su; David N Garboczi Journal: J Virol Date: 2016-04-29 Impact factor: 5.103
Authors: Thomas Kaever; Michael H Matho; Xiangzhi Meng; Lindsay Crickard; Andrew Schlossman; Yan Xiang; Shane Crotty; Bjoern Peters; Dirk M Zajonc Journal: J Virol Date: 2016-04-14 Impact factor: 5.103